NLNK Fails To Impress, TBPH Gets FDA Nod, It's A Make Or Break Month For TNXP

Shares of NewLink Genetics Corp. (NLNK) plunged over 30% in after-hours Monday, following the company's failure of phase III study of algenpantucel-L for patients with resected pancreatic cancer to achieve its primary endpoint.

from RTT - Biotech http://ift.tt/1TBy9yB
via IFTTT